Everything below concerns epithalamin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Linear tetrapeptide | Four residues joined by three peptide bonds |
| Sequence | Ala-Glu-Asp-Gly | Commonly abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free acid form |
| Monoisotopic mass | Approximately 390 Da | Matches values reported from mass spectrometry |
| Net charge near neutral pH | Negative | Contributed by glutamate and aspartate side chains |
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
== Television episodes == "Half-Life", Icons season 3, episode 17 (2004) "Half-Life", Odyssey 5 episode 17 (2002) "Half Life", La Femme Nikita season 2, episode 7 (1998) "Half Life", Logan's Run episode 6 (1977) "Half Life", Medical Investigation episode 17 (2005) "Half Life", New Tricks series 8, episode 9 (2011) "Half Life", Sea Patrol season 3, episode 7 (2009) "Half Life", SeaChange season 3, episode 13 (2000)
Rl = Xwαl/wRw + (1 − Xw)αl/sRs, where Rl, Rw, and Rs are the DHRs of lipids, water, and substrates, respectively. Xw is the mole fraction of lipid H derived from external water, whereas αl/w and αl/s denote the net isotopic fractionations associated with uptake and utilization of water and substrate hydrogen, respectively. For phototrophs, Rl is calculated assuming that Xw = 1. The isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids. The isotopic fractionation between lipids and water (αl/w) is 0.95 for fatty acids and 0.85 for isoprenoid lipids. For plants and algae, the isotopic fractionation between lipids and methane (αl/m) is 0.94 for fatty acids and 0.79 for isoprenoid lipids.
== Medical use == Branched-chain alpha-keto acids such as α-KIC are found in high concentrations in the urine of people who suffer from Maple Syrup Urine Disease. This is disease is caused by a partial branched-chain alpha-keto acid dehydrogenase deficiency, which leads to a buildup of branched-chain alpha-keto acids, including α-KIC and HMB. These keto-acids build up in the liver, and since limited isovaleryl-CoA can be produced, these keto-acids must be excreted in the urine as α-KIC, HMB, and many other similar keto acids. Flare-ups in people who have this condition are caused due to poor diet. Symptoms of Maple Syrup Urine Disease include sweet smelling urine, irritability, lethargy, and in serious cases edema of the brain, apnea, coma, or respiratory failure. Treatment includes lowering leucine intake and a specialized diet to make up for the lack of leucine ingestion.
Sources: en.wikipedia.org
Illicit drug use in Mexico is low compared to the United States, but it is on the rise, with the availability of narcotics gradually increasing since the 1980s. The export rate of cocaine to the US decreased following stricter border control measures in response to the September 11 attacks. Drug shipments are often delayed in Mexican border towns before delivery to the U.S., which has forced drug traffickers to increase prices to account for transportation costs. These delays have contributed to the increased rates of local drug consumption. As a result of "spillover" along the U.S.-bound drug trafficking routes and more stringent border enforcement, Mexico's northern border states have seen increased levels of drug consumption and abuse, including elevated rates of drug injection, up to 10 to 15 times the national average. These rates are accompanied by mounting rates of HIV and STIs among injection drug users (IDUs) and sex workers, reaching a 5.5% prevalence in cities such as Tijuana and Ciudad Juárez, which also report STI rates of 64% and 83%, respectively. Violence and extortion of IDUs and sex workers directly and indirectly elevate the levels of risk behavior and poor health outcomes among members of these groups. Marginalization of these vulnerable groups by way of physical and sexual violence and extortion by police threatens the cross-over of infection from high-prevalence groups to the general population.
The protecting group is abbreviated Cbz or, in honour of Zervas, simply Z. The typical route for deprotection involves hydrogenolysis under mild conditions e.g. with hydrogen gas and a catalyst such as palladium on charcoal. The discovery of the Bergmann-Zervas synthesis has been characterised as "epoch-making" as it allowed the advent of controlled synthetic peptide chemistry, completing the work started in the early 20th century by Bergmann's mentor Emil Fischer. Previously impossible to synthesise oligopeptides with a highly specific sequence and reactive side chains were consequently produced in the 1930s by Bergmann and Zervas. The ability of Z-protection to prevent racemization of activated derivatives of the protected amino acids and the importance thereof were also noted by the two chemists. Indeed, their method became the standard in the field for the following two decades until further developments in the early 1950s with the introduction of mixed anhydrides (e.g. the Boc group).
Dystrophic epidermolysis bullosa (DEB) is an inherited variant affecting the skin and other organs. DEB is caused by genetic defects (or mutations) within the human COL7A1 gene encoding the protein type VII collagen (collagen VII). DEB-causing mutations can be either autosomal dominant or autosomal recessive. Epidermolysis bullosa pruriginosa and albopapuloid epidermolysis bullosa (Pasini disease) are rare subtypes of this disease.
Sources: en.wikipedia.org
Tools such as GPTZero can detect content generated by AI. However, they can also make false accusations (false positives). Digital watermarking is a technique that improves detection accuracy. It works by altering the generated content at the source, in subtle ways which can be detected by corresponding software. In 2023, OpenAI developed a watermarking tool for ChatGPT. However, it was not released, because they worried that users would switch to competitors. They also argued that it would be easy to circumvent, for example by asking another AI to rephrase. In March 2025, China issued requirements for online service providers to label AI content. In May 2025, Google deployed its watermarking tool, SynthID. It marks output from Gemini (text), Imagen (images), and Veo (video). To detect output from these products, one uses Google's "SynthID detector" portal. In 2025, users mistakenly accused gaming companies of using generative AI for the video games Little Droid and Chessplus.
== Further reading == Baena-Cagnani CE (2001). "Desloratadine activity in concurrent seasonal allergic rhinitis and asthma". Allergy. 56 Suppl 65: 21–7. doi:10.1111/j.1398-9995.2001.00001.x-i1. PMID 11243501. Devillier P, Roche N, Faisy C (2008). "Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review". Clinical Pharmacokinetics. 47 (4): 217–30. doi:10.2165/00003088-200847040-00001. PMID 18336052. Geha RS, Meltzer EO (April 2001). "Desloratadine: A new, nonsedating, oral antihistamine". The Journal of Allergy and Clinical Immunology. 107 (4): 751–62. doi:10.1067/mai.2001.114239. PMID 11295678. Henz BM (2001). "The pharmacologic profile of desloratadine: a review". Allergy. 56 Suppl 65: 7–13. doi:10.1034/j.1398-9995.2001.00101.x. PMID 11243504.
== History == Ubrogepant, also known as MK-1602, was discovered by scientists at Merck in 2020. The effectiveness of ubrogepant for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials. In these studies, 1,439 adult patients with a history of migraine, with and without aura, received the approved doses of ubrogepant to treat an ongoing migraine. In both studies, the percentages of patients achieving pain relief two hours after treatment (defined as a reduction in headache severity from moderate or severe pain to no pain) and whose most bothersome migraine symptom (nausea, light sensitivity or sound sensitivity) stopped two hours after treatment were significantly greater among patients receiving ubrogepant (19–21% depending on the dose) compared to those receiving placebo (12%). Patients were allowed to take their usual acute treatment of migraine at least two hours after taking ubrogepant. 23% of patients were taking a preventive medication for migraine. In December 2019, the US Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.
The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.
The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.